Bioventus Inc. (BVS)
| Market Cap | 830.50M |
| Revenue (ttm) | 568.09M |
| Net Income (ttm) | 22.73M |
| Shares Out | 83.43M |
| EPS (ttm) | 0.33 |
| PE Ratio | 30.17 |
| Forward PE | 13.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 299,833 |
| Open | 10.09 |
| Previous Close | 10.01 |
| Day's Range | 9.87 - 10.30 |
| 52-Week Range | 5.81 - 10.76 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+40.7%) |
| Earnings Date | May 6, 2026 |
About BVS
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price target is $14.0, which is an increase of 40.70% from the latest price.
News
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fin...
Bioventus Earnings Call Transcript: Q4 2025
Q4 2025 saw 10% organic revenue growth, record cash from operations, and margin expansion. 2026 guidance projects $600–$610 million in sales, with investments in PNS, PRP, Ultrasonics, and international driving future growth.
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP ea...
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Bioventus Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant transformation has led to above-market growth, high margins, and strong cash flow. Four growth drivers—ultrasonics, international, PNS, and PRP—are set to accelerate future performance, with disciplined investment and a focus on debt reduction.
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will prese...
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investig...
Bioventus Transcript: Piper Sandler 37th Annual Healthcare Conference
The presentation highlighted strong above-market growth, peer-leading margins, and a robust innovation pipeline across core, expansion, and emerging segments. Cash flow and leverage improvements are enabling greater capital flexibility, supporting the goal of reaching $1 billion in revenue.
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Execu...
Bioventus Earnings Call Transcript: Q3 2025
Q3 saw 8% organic revenue growth, margin expansion, and strong cash flow, with all segments contributing and new product launches gaining traction. 2025 guidance was reaffirmed, and debt reduction remains on track, positioning for continued profitable growth.
Bioventus Reports Third Quarter Financial Results
DURHAM, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for th...
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to sha...
Bioventus Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A diversified medical device company has executed a successful turnaround, focusing on high-margin growth in pain, surgical, and restorative therapies. Key drivers include ultrasonics, HA, and new PRP and PNS launches, with disciplined investment and a focus on debt reduction.
Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, Bioventus Senior Vice-President a...
Bioventus Transcript: Canaccord Genuity’s 45th Annual Growth Conference
The company is driving above-market growth across pain, surgical, and restorative therapies, with strong financial discipline leading to improved margins, cash flow, and reduced leverage. Emerging businesses in PNS and PRP, along with international expansion, are set to accelerate growth from 2026.
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Execu...
Bioventus Earnings Call Transcript: Q2 2025
Q2 2025 saw 6% organic growth, strong profitability, and robust cash flow, with FDA clearance for new PNS products opening a $2B market opportunity. Full-year guidance was reaffirmed despite $5M in FX and tariff headwinds, and refinancing improved liquidity and reduced interest costs.
Bioventus Reports Second Quarter Financial Results
DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the...
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into...
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Adm...
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fina...
Bioventus Earnings Call Transcript: Q1 2025
Q1 organic revenue grew 5% to $124M, with adjusted EPS up 33% to $0.08. Full-year guidance for 6%-8% organic growth, $112-$116M adjusted EBITDA, and $0.64-$0.68 EPS was reaffirmed, with second-half acceleration expected.
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the ...
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report fin...